Objective: Notch signalings are regulated multiple cellular processes during cancer progression. We aimed to investigate the significance and prognostic value of expression of Notch1 and JAG1 in cervical cancer to determine whether they could serve as prognostic predictors.
Methods/materials: The expression of Notch1/JAGD1 was investigated by real-time PCR, western blot assay and its association with overall survival of patients was analyzed by statistical analysis.
Results: Notch1 and JAGD1 expression level were significantly elevated in cervical cancer in comparison to normal specimens and other types of Notch receptors and ligands. It is also proved that Notch1 and JAGD1 expression were to be associated with cervical cancer invasion, lymph node metastasis, and FIGO system. In addition, survival analysis proved that elevated Notch1 and JAGD1 expression were associated with poor overall survival of patients (P = 0.01, P = 0.02 log-rank test), respectively.
Conclusions: The present data proved the over-expression of Notch1/JAGD1 and its association with tumor progression in human cervical cancer, which might be a potential valuable biomarker for cervical cancer and further studies need.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1007/s00404-015-3694-1 | DOI Listing |
Reprod Health
January 2025
Department of Obstetrics and Gynecology, School of Medicine, University of California Irvine, Irvine, CA, USA.
Background: Refugee women's reproductive health (RH) outcomes have been impacted by several factors, including experiencing war, lack of access to healthcare, and possible gender-based violence. After resettlement, low health literacy, financial difficulties, cultural and linguistic barriers, and unfamiliarity with the healthcare system also add to the preexisting barriers. Although several efforts have focused on health education and improving health literacy among refugee women, there has not been a validated tool to measure the effectiveness of these trainings and their possible impact.
View Article and Find Full Text PDFBMC Public Health
January 2025
Icahn School of Medicine at Mount Sinai, New York, NY, USA.
Background: Disparities in lung cancer outcomes persist among Black Americans, necessitating targeted interventions to address screening inequities. This paper reports the development and refinement of Witness Project Lung, a community-based initiative tailored to the specific needs of the Black community, aiming to improve awareness and engagement with lung cancer screening.
Methods: Utilizing a user-centered design and guided by the original Witness Project framework - an evidence-based lay health advisor intervention program originally developed to increase knowledge and awareness about breast cancer risk and screening in the Black community and later trans-created to the cervical and colorectal cancer screening contexts - Witness Project Lung was developed and refined through qualitative input from key stakeholders in the Black faith community.
Ann Surg Oncol
January 2025
Department of Obstetrics and Gynecology, Osaka Rosai Hospital, Sakai, Osaka, Japan.
Reprod Sci
January 2025
Department of Radiation Oncology, Lianyungang No.2 People's Hospital, Lianyungang, China.
Cervical cancer (CC) represents a major gynecologic health problem. Respecting the role of programmed cell death ligand-1 (PDL-1) in cancer prognosis, we investigated its relationship with cervical squamous cell carcinoma (CSCC) invasion, metastasis and prognosis. A total of 184 CSCC patients were retrospectively selected, with normal paracarcinoma tissues as the Control group.
View Article and Find Full Text PDFGynecol Obstet Fertil Senol
February 2025
Service de gynécologie obstétrique, hôpital Nord, CHU de Marseille, chemin des Bourrely, 13015 Marseille, France. Electronic address:
Objective: To update the recommendations issued by the National Cancer Institute (INCa) on the management of women with abnormal cervical cytology.
Methods: INCa recommendations on the management of women with abnormal cervical cytology were published in 2016. In 2019, the High Authority of Health (HAS) recommends HPV test for cervical cancer screening in women over 30.
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!